RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) was upgraded by equities research analysts at HC Wainwright to a "strong-buy" rating in a report released on Thursday, Marketbeat.com reports. The brokerage currently has a $6.00 price objective on the stock.
RAPT Therapeutics Stock Down 21.8%
RAPT traded down $0.27 during trading on Thursday, reaching $0.96. 1,408,376 shares of the company's stock were exchanged, compared to its average volume of 1,278,791. RAPT Therapeutics has a fifty-two week low of $0.71 and a fifty-two week high of $4.60. The business has a 50 day moving average price of $0.98 and a 200 day moving average price of $1.14. The company has a market capitalization of $127.26 million, a P/E ratio of -0.35 and a beta of -0.04.
RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.23. As a group, research analysts forecast that RAPT Therapeutics will post -2.14 EPS for the current year.
Institutional Investors Weigh In On RAPT Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC boosted its stake in shares of RAPT Therapeutics by 401.9% in the 4th quarter. SG Americas Securities LLC now owns 53,244 shares of the company's stock valued at $84,000 after purchasing an additional 42,636 shares in the last quarter. Sei Investments Co. acquired a new stake in shares of RAPT Therapeutics in the 4th quarter valued at $64,000. Barclays PLC boosted its stake in shares of RAPT Therapeutics by 277.2% in the 3rd quarter. Barclays PLC now owns 39,729 shares of the company's stock valued at $79,000 after purchasing an additional 29,195 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of RAPT Therapeutics by 1,128.3% in the 4th quarter. JPMorgan Chase & Co. now owns 205,164 shares of the company's stock valued at $324,000 after purchasing an additional 188,461 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of RAPT Therapeutics by 25.5% in the 4th quarter. Renaissance Technologies LLC now owns 369,736 shares of the company's stock valued at $584,000 after purchasing an additional 75,136 shares in the last quarter. Institutional investors and hedge funds own 99.09% of the company's stock.
About RAPT Therapeutics
(
Get Free Report)
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Featured Articles
Before you consider RAPT Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RAPT Therapeutics wasn't on the list.
While RAPT Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
